Ticker Scorecard - AMLX Basics Company: Amylyx Pharmaceuticals, Inc. IPO Date: January 7, 2022 Sector: Healthcare Industry: Biotech Market Cap: $274.19M Activated in VL: True Average Daily Range Avg Daily Range: $0.56 | 3.39% Avg Daily Range (30 D): $0.15 | 3.36% Avg Daily Range (90 D): $0.16 | 3.87% Institutional Daily Volume Avg Daily Volume: 1.16M Avg Daily Volume (30 D): .61M Avg Daily Volume (90 D): 1.14M Trade Size Avg Trade Size (Sh.): 96 Avg Trade Size (Sh.) (30 D): 100 Avg Trade Size (Sh.) (90 D): 123 Institutional Trades Total Inst.Trades: 1,263 Avg Inst. Trade: $1.83M Avg Inst. Trade (30 D): $1.87M Avg Inst. Trade (90 D): $1.37M Avg Inst. Trade Volume: .1M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $2.3M Avg Closing Trade (30 D): $.85M Avg Closing Trade (90 D): $.95M Avg Closing Volume: 132.42K     News Oct 18, 2024 @ 11:26 AM Why Amylyx Pharmaceuticals Stock Was So Healthy Th... Source: Eric Volkman May 10, 2024 @ 6:01 PM Breaking Down Amylyx Pharma: 9 Analysts Share Thei... Source: Benzinga Insights May 9, 2024 @ 12:15 PM Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Los... Source: Zacks Equity Research Apr 12, 2024 @ 1:22 PM The Zacks Analyst Blog Highlights Bristol Myers, M... Source: Zacks Equity Research Apr 10, 2024 @ 5:19 PM Biotech Stock Roundup: MRNA Up on Vaccine Data, BM... Source: Zacks Equity Research Financials   TTM Q3 2024 Q2 2024 Basic EPS $-3.82 $-1.07 $-1.07 Diluted EPS $-3.82 $-1.07 $-1.07 Revenue $ 196.49M $ .42M $ -1.02M Gross Profit $ 181.17M $ .42M $ -1.03M Net Income / Loss $ -259.47M $ -72.7M $ -72.7M Operating Income / Loss $ -272.14M $ -75.66M $ -76.29M Cost of Revenue $ 15.31M $ M $ .01M Net Cash Flow $ -62.7M $ -2.44M $ -95.55M PE Ratio